- Home
- ODD vs KYMR Comparison
ODD vs KYMR Comparison
Compare ODD & KYMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ODD
- KYMR
- Stock Information
- Founded
- ODD 2018
- KYMR 2015
- Country
- ODD Israel
- KYMR United States
- Employees
- ODD N/A
- KYMR N/A
- Industry
- ODD
- KYMR Medicinal Chemicals and Botanical Products
- Sector
- ODD
- KYMR Health Care
- Exchange
- ODD Nasdaq
- KYMR Nasdaq
- Market Cap
- ODD 2.5B
- KYMR 2.7B
- IPO Year
- ODD 2023
- KYMR 2020
- Fundamental
- Price
- ODD $44.00
- KYMR $36.81
- Analyst Decision
- ODD Buy
- KYMR Buy
- Analyst Count
- ODD 9
- KYMR 15
- Target Price
- ODD $53.33
- KYMR $55.27
- AVG Volume (30 Days)
- ODD 363.5K
- KYMR 456.1K
- Earning Date
- ODD 02-25-2025
- KYMR 02-27-2025
- Dividend Yield
- ODD N/A
- KYMR N/A
- EPS Growth
- ODD 80.44
- KYMR N/A
- EPS
- ODD 1.64
- KYMR N/A
- Revenue
- ODD $620,646,000.00
- KYMR $87,563,000.00
- Revenue This Year
- ODD $27.70
- KYMR N/A
- Revenue Next Year
- ODD $20.14
- KYMR $32.89
- P/E Ratio
- ODD $26.82
- KYMR N/A
- Revenue Growth
- ODD 29.59
- KYMR 86.92
- 52 Week Low
- ODD $30.34
- KYMR $29.24
- 52 Week High
- ODD $51.00
- KYMR $53.27
- Technical
- Relative Strength Index (RSI)
- ODD 48.47
- KYMR 42.51
- Support Level
- ODD $43.16
- KYMR $36.67
- Resistance Level
- ODD $46.00
- KYMR $38.24
- Average True Range (ATR)
- ODD 2.18
- KYMR 1.78
- MACD
- ODD -0.07
- KYMR 0.06
- Stochastic Oscillator
- ODD 41.49
- KYMR 51.81
About ODD ODDITY Tech Ltd.
ODDITY Tech Ltd offers a consumer tech platform that is built to transform the beauty and wellness market. The ODDITY platform is designed to support a portfolio of brands and services that innovate and disrupt the expansive beauty and wellness market. It consumes user data to develop physical beauty and wellness products that deliver performance and functionality. Its brands include SpoiledChild and IL Makiage.
About KYMR Kymera Therapeutics Inc.
Kymera Therapeutics Inc is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. The company is advancing the field of targeted protein degradation, accessing the body's innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Kymera's Pegasus targeted protein degradation platform harnesses the body's natural protein recycling machinery to degrade disease-causing proteins, with a focus on un-drugged nodes in validated pathways currently inaccessible with conventional therapeutics. It is accelerating drug discovery with an unmatched ability to target and degrade intractable proteins and advance new treatment options for patients.